11.11 USD
-0.07 (-0.63%)
11.14 USD
+0.03 (+0.27%)
Taking everything into account, XRAY scores 4 out of 10 in our fundamental rating. XRAY was compared to 188 industry peers in the Health Care Equipment & Supplies industry. There are concerns on the financial health of XRAY while its profitability can be described as average. XRAY has a bad growth rate and is valued cheaply. Finally XRAY also has an excellent dividend rating.
1. Profitability
1.1 Basic Checks
In the past year XRAY was profitable.
In the past year XRAY had a positive cash flow from operations.
In the past 5 years XRAY reported 4 times negative net income.
XRAY had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of XRAY (-15.60%) is comparable to the rest of the industry.
XRAY's Return On Equity of -59.68% is in line compared to the rest of the industry. XRAY outperforms 48.40% of its industry peers.
XRAY has a Return On Invested Capital of 5.04%. This is in the better half of the industry: XRAY outperforms 76.60% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for XRAY is below the industry average of 8.78%.
The last Return On Invested Capital (5.04%) for XRAY is above the 3 year average (4.11%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -15.6% | ||
| ROE | -59.68% | ||
| ROIC | 5.04% |
ROA(3y)-10.01%
ROA(5y)-5.27%
ROE(3y)-25.27%
ROE(5y)-13.81%
ROIC(3y)4.11%
ROIC(5y)4.26%
1.3 Margins
With a decent Operating Margin value of 7.48%, XRAY is doing good in the industry, outperforming 73.40% of the companies in the same industry.
In the last couple of years the Operating Margin of XRAY has declined.
XRAY has a Gross Margin (51.10%) which is comparable to the rest of the industry.
In the last couple of years the Gross Margin of XRAY has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.48% | ||
| PM (TTM) | N/A | ||
| GM | 51.1% |
OM growth 3Y-25.8%
OM growth 5Y-12.74%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.16%
GM growth 5Y-0.95%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), XRAY is destroying value.
The number of shares outstanding for XRAY has been reduced compared to 1 year ago.
The number of shares outstanding for XRAY has been reduced compared to 5 years ago.
Compared to 1 year ago, XRAY has a worse debt to assets ratio.
2.2 Solvency
XRAY has an Altman-Z score of 0.92. This is a bad value and indicates that XRAY is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.92, XRAY is in line with its industry, outperforming 52.13% of the companies in the same industry.
The Debt to FCF ratio of XRAY is 29.94, which is on the high side as it means it would take XRAY, 29.94 years of fcf income to pay off all of its debts.
XRAY's Debt to FCF ratio of 29.94 is fine compared to the rest of the industry. XRAY outperforms 68.09% of its industry peers.
XRAY has a Debt/Equity ratio of 1.36. This is a high value indicating a heavy dependency on external financing.
XRAY has a worse Debt to Equity ratio (1.36) than 78.72% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.36 | ||
| Debt/FCF | 29.94 | ||
| Altman-Z | 0.92 |
ROIC/WACC0.82
WACC6.11%
2.3 Liquidity
A Current Ratio of 1.47 indicates that XRAY should not have too much problems paying its short term obligations.
XRAY has a worse Current ratio (1.47) than 76.06% of its industry peers.
A Quick Ratio of 0.99 indicates that XRAY may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.99, XRAY is doing worse than 76.06% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.47 | ||
| Quick Ratio | 0.99 |
3. Growth
3.1 Past
The earnings per share for XRAY have decreased strongly by -14.59% in the last year.
Measured over the past years, XRAY shows a decrease in Earnings Per Share. The EPS has been decreasing by -7.38% on average per year.
Looking at the last year, XRAY shows a decrease in Revenue. The Revenue has decreased by -7.08% in the last year.
Measured over the past years, XRAY shows a decrease in Revenue. The Revenue has been decreasing by -1.17% on average per year.
EPS 1Y (TTM)-14.59%
EPS 3Y-16.51%
EPS 5Y-7.38%
EPS Q2Q%-26%
Revenue 1Y (TTM)-7.08%
Revenue growth 3Y-3.58%
Revenue growth 5Y-1.17%
Sales Q2Q%-4.94%
3.2 Future
Based on estimates for the next years, XRAY will show a small growth in Earnings Per Share. The EPS will grow by 7.40% on average per year.
The Revenue is expected to grow by 1.34% on average over the next years.
EPS Next Y14.71%
EPS Next 2Y11.04%
EPS Next 3Y10.19%
EPS Next 5Y7.4%
Revenue Next Year-4.07%
Revenue Next 2Y-1.35%
Revenue Next 3Y0.15%
Revenue Next 5Y1.34%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 7.03, the valuation of XRAY can be described as very cheap.
Based on the Price/Earnings ratio, XRAY is valued cheaply inside the industry as 97.34% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 26.15. XRAY is valued rather cheaply when compared to this.
Based on the Price/Forward Earnings ratio of 5.40, the valuation of XRAY can be described as very cheap.
XRAY's Price/Forward Earnings ratio is rather cheap when compared to the industry. XRAY is cheaper than 98.94% of the companies in the same industry.
XRAY is valuated cheaply when we compare the Price/Forward Earnings ratio to 36.22, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.03 | ||
| Fwd PE | 5.4 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of XRAY indicates a rather cheap valuation: XRAY is cheaper than 96.28% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, XRAY is valued cheaply inside the industry as 80.85% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 27.71 | ||
| EV/EBITDA | 6.88 |
4.3 Compensation for Growth
XRAY's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)0.48
PEG (5Y)N/A
EPS Next 2Y11.04%
EPS Next 3Y10.19%
5. Dividend
5.1 Amount
XRAY has a Yearly Dividend Yield of 4.91%, which is a nice return.
In the last 3 months the price of XRAY has falen by -24.01%. A price decline artificially increases the dividend yield. It may be a sign investors do not expect the dividend to last.
Compared to an average industry Dividend Yield of 1.71, XRAY pays a better dividend. On top of this XRAY pays more dividend than 100.00% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 2.32, XRAY pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.91% |
5.2 History
On average, the dividend of XRAY grows each year by 11.21%, which is quite nice.
XRAY has been paying a dividend for at least 10 years, so it has a reliable track record.
XRAY has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.
Dividend Growth(5Y)11.21%
Div Incr Years6
Div Non Decr Years30
5.3 Sustainability
XRAY has negative earnings and hence a negative payout ratio. The dividend may be in danger.
The dividend of XRAY is growing, but the earnings are growing slower. This means the dividend growth is not sustainable.
DP-14.4%
EPS Next 2Y11.04%
EPS Next 3Y10.19%
11.11
-0.07 (-0.63%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners104.22%
Inst Owner Change9.76%
Ins Owners0.32%
Ins Owner Change-0.78%
Market Cap2.22B
Revenue(TTM)3.62B
Net Income(TTM)-882.00M
Analysts70.91
Price Target12.99 (16.92%)
Short Float %6.77%
Short Ratio3.73
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.91% |
Yearly Dividend0.62
Dividend Growth(5Y)11.21%
DP-14.4%
Div Incr Years6
Div Non Decr Years30
Ex-Date
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-8.77%
Min EPS beat(2)-19.03%
Max EPS beat(2)1.49%
EPS beat(4)2
Avg EPS beat(4)-3.17%
Min EPS beat(4)-40.52%
Max EPS beat(4)45.37%
EPS beat(8)3
Avg EPS beat(8)-1.68%
EPS beat(12)6
Avg EPS beat(12)4.59%
EPS beat(16)7
Avg EPS beat(16)1.99%
Revenue beat(2)0
Avg Revenue beat(2)-1.42%
Min Revenue beat(2)-1.67%
Max Revenue beat(2)-1.16%
Revenue beat(4)1
Avg Revenue beat(4)-1.42%
Min Revenue beat(4)-3.62%
Max Revenue beat(4)0.77%
Revenue beat(8)2
Avg Revenue beat(8)-1.44%
Revenue beat(12)5
Avg Revenue beat(12)-0.9%
Revenue beat(16)5
Avg Revenue beat(16)-2.02%
PT rev (1m)-23.42%
PT rev (3m)-24.18%
EPS NQ rev (1m)-41.26%
EPS NQ rev (3m)-42.18%
EPS NY rev (1m)-0.2%
EPS NY rev (3m)-0.56%
Revenue NQ rev (1m)-1.56%
Revenue NQ rev (3m)-1.3%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.03%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.03 | ||
| Fwd PE | 5.4 | ||
| P/S | 0.61 | ||
| P/FCF | 27.71 | ||
| P/OCF | 10.03 | ||
| P/B | 1.5 | ||
| P/tB | N/A | ||
| EV/EBITDA | 6.88 |
EPS(TTM)1.58
EY14.22%
EPS(NY)2.06
Fwd EY18.53%
FCF(TTM)0.4
FCFY3.61%
OCF(TTM)1.11
OCFY9.97%
SpS18.16
BVpS7.41
TBVpS-4.29
PEG (NY)0.48
PEG (5Y)N/A
Graham Number16.23
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -15.6% | ||
| ROE | -59.68% | ||
| ROCE | 6.38% | ||
| ROIC | 5.04% | ||
| ROICexc | 5.51% | ||
| ROICexgc | 13.81% | ||
| OM | 7.48% | ||
| PM (TTM) | N/A | ||
| GM | 51.1% | ||
| FCFM | 2.21% |
ROA(3y)-10.01%
ROA(5y)-5.27%
ROE(3y)-25.27%
ROE(5y)-13.81%
ROIC(3y)4.11%
ROIC(5y)4.26%
ROICexc(3y)4.36%
ROICexc(5y)4.5%
ROICexgc(3y)15.64%
ROICexgc(5y)20.94%
ROCE(3y)5.38%
ROCE(5y)5.49%
ROICexgc growth 3Y-31.16%
ROICexgc growth 5Y-12.42%
ROICexc growth 3Y-13.44%
ROICexc growth 5Y-4.44%
OM growth 3Y-25.8%
OM growth 5Y-12.74%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.16%
GM growth 5Y-0.95%
F-Score4
Asset Turnover0.64
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.36 | ||
| Debt/FCF | 29.94 | ||
| Debt/EBITDA | 3.26 | ||
| Cap/Depr | 40.63% | ||
| Cap/Sales | 3.89% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 35.76% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.47 | ||
| Quick Ratio | 0.99 | ||
| Altman-Z | 0.92 |
F-Score4
WACC6.11%
ROIC/WACC0.82
Cap/Depr(3y)46.81%
Cap/Depr(5y)41.51%
Cap/Sales(3y)4.1%
Cap/Sales(5y)3.65%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-14.59%
EPS 3Y-16.51%
EPS 5Y-7.38%
EPS Q2Q%-26%
EPS Next Y14.71%
EPS Next 2Y11.04%
EPS Next 3Y10.19%
EPS Next 5Y7.4%
Revenue 1Y (TTM)-7.08%
Revenue growth 3Y-3.58%
Revenue growth 5Y-1.17%
Sales Q2Q%-4.94%
Revenue Next Year-4.07%
Revenue Next 2Y-1.35%
Revenue Next 3Y0.15%
Revenue Next 5Y1.34%
EBIT growth 1Y3.04%
EBIT growth 3Y-28.45%
EBIT growth 5Y-13.75%
EBIT Next Year53.77%
EBIT Next 3Y18.64%
EBIT Next 5Y11.96%
FCF growth 1Y-63.3%
FCF growth 3Y-18.29%
FCF growth 5Y-11.45%
OCF growth 1Y-38.44%
OCF growth 3Y-11.14%
OCF growth 5Y-6.32%
DENTSPLY SIRONA INC / XRAY FAQ
Can you provide the ChartMill fundamental rating for DENTSPLY SIRONA INC?
ChartMill assigns a fundamental rating of 4 / 10 to XRAY.
Can you provide the valuation status for DENTSPLY SIRONA INC?
ChartMill assigns a valuation rating of 8 / 10 to DENTSPLY SIRONA INC (XRAY). This can be considered as Undervalued.
How profitable is DENTSPLY SIRONA INC (XRAY) stock?
DENTSPLY SIRONA INC (XRAY) has a profitability rating of 4 / 10.
What is the valuation of DENTSPLY SIRONA INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for DENTSPLY SIRONA INC (XRAY) is 7.03 and the Price/Book (PB) ratio is 1.5.
How sustainable is the dividend of DENTSPLY SIRONA INC (XRAY) stock?
The dividend rating of DENTSPLY SIRONA INC (XRAY) is 7 / 10 and the dividend payout ratio is -14.4%.